Novel treatment options in depression and psychosis

Eva Ceskova, Petr Silhan Department of Psychiatry, University Hospital Ostrava, Ostrava, Czech Republic Abstract: In spite of tremendous development in central nervous system research, current treatment is suboptimal, especially in severe mental disorders. In medicine, there are two main methods o...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ceskova E, Silhan P
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2018
Materias:	optimization of treatment multimodal/multifunctional antidepressants partial dopamine agonists glutamate modulators nicotine receptors agonists Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/185ab8856f044f8d9305cd8f6551dd3f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:185ab8856f044f8d9305cd8f6551dd3f
record_format	dspace
spelling	oai:doaj.org-article:185ab8856f044f8d9305cd8f6551dd3f2021-12-02T02:17:52ZNovel treatment options in depression and psychosis1178-2021https://doaj.org/article/185ab8856f044f8d9305cd8f6551dd3f2018-03-01T00:00:00Zhttps://www.dovepress.com/novel-treatment-options-in-depression-and-psychosis-peer-reviewed-article-NDThttps://doaj.org/toc/1178-2021Eva Ceskova, Petr Silhan Department of Psychiatry, University Hospital Ostrava, Ostrava, Czech Republic Abstract: In spite of tremendous development in central nervous system research, current treatment is suboptimal, especially in severe mental disorders. In medicine, there are two main methods of improving the health care provided: seeking new treatment procedures and perfecting (optimizing) the existing ones. Optimization of treatment includes not only practical tools such as therapeutic drug monitoring but also implementation of general trends in the clinical practice. New pharmacological options include new more sophisticated forms of monoaminergic drugs, old drugs rediscovered on the base of a better understanding of pathophysiology of mental illnesses, and drugs aimed at new treatment targets. In depression, treatment resistance to antidepressive pharmacotherapy represents one of the most important clinical challenges. Switching to monotherapy with new multimodal/multifunctional antidepressants and augmentation with new atypical antipsychotics (aripiprazole and brexpiprazole) may be promising options. Further, current evidence supports utility and safety of adjunctive treatment of nutraceuticals. Novel approaches being studied include ketamine and opioids. Recent advances in technology and emerging knowledge about dysfunctional brain circuits and neuroplasticity have led to the development of different new neuromodulation techniques usually used as add-on therapy. Antipsychotics are still the cornerstone of the current treatment of schizophrenia. Two new partial dopamine agonists, brexpiprazole and cariprazine, are now available in addition to aripiprazole. Although the mechanisms of action are similar, the two agents differ in terms of their pharmacodynamic profiles. Further, two new formulations of long-acting injections of second-generation antipsychotics (aripiprazole lauroxil and 3-month paliperidone palmitate) were introduced into clinical practice. New treatment options not yet available include cannabidiol, glutamate modulators, and nicotine receptors agonists. Keywords: optimization of treatment, multimodal/multifunctional antidepressants, partial dopamine agonists, glutamate modulators, nicotine receptors agonistsCeskova ESilhan PDove Medical Pressarticleoptimization of treatmentmultimodal/multifunctional antidepressantspartial dopamine agonistsglutamate modulatorsnicotine receptors agonistsNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol Volume 14, Pp 741-747 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	optimization of treatment multimodal/multifunctional antidepressants partial dopamine agonists glutamate modulators nicotine receptors agonists Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	optimization of treatment multimodal/multifunctional antidepressants partial dopamine agonists glutamate modulators nicotine receptors agonists Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Ceskova E Silhan P Novel treatment options in depression and psychosis
description	Eva Ceskova, Petr Silhan Department of Psychiatry, University Hospital Ostrava, Ostrava, Czech Republic Abstract: In spite of tremendous development in central nervous system research, current treatment is suboptimal, especially in severe mental disorders. In medicine, there are two main methods of improving the health care provided: seeking new treatment procedures and perfecting (optimizing) the existing ones. Optimization of treatment includes not only practical tools such as therapeutic drug monitoring but also implementation of general trends in the clinical practice. New pharmacological options include new more sophisticated forms of monoaminergic drugs, old drugs rediscovered on the base of a better understanding of pathophysiology of mental illnesses, and drugs aimed at new treatment targets. In depression, treatment resistance to antidepressive pharmacotherapy represents one of the most important clinical challenges. Switching to monotherapy with new multimodal/multifunctional antidepressants and augmentation with new atypical antipsychotics (aripiprazole and brexpiprazole) may be promising options. Further, current evidence supports utility and safety of adjunctive treatment of nutraceuticals. Novel approaches being studied include ketamine and opioids. Recent advances in technology and emerging knowledge about dysfunctional brain circuits and neuroplasticity have led to the development of different new neuromodulation techniques usually used as add-on therapy. Antipsychotics are still the cornerstone of the current treatment of schizophrenia. Two new partial dopamine agonists, brexpiprazole and cariprazine, are now available in addition to aripiprazole. Although the mechanisms of action are similar, the two agents differ in terms of their pharmacodynamic profiles. Further, two new formulations of long-acting injections of second-generation antipsychotics (aripiprazole lauroxil and 3-month paliperidone palmitate) were introduced into clinical practice. New treatment options not yet available include cannabidiol, glutamate modulators, and nicotine receptors agonists. Keywords: optimization of treatment, multimodal/multifunctional antidepressants, partial dopamine agonists, glutamate modulators, nicotine receptors agonists
format	article
author	Ceskova E Silhan P
author_facet	Ceskova E Silhan P
author_sort	Ceskova E
title	Novel treatment options in depression and psychosis
title_short	Novel treatment options in depression and psychosis
title_full	Novel treatment options in depression and psychosis
title_fullStr	Novel treatment options in depression and psychosis
title_full_unstemmed	Novel treatment options in depression and psychosis
title_sort	novel treatment options in depression and psychosis
publisher	Dove Medical Press
publishDate	2018
url	https://doaj.org/article/185ab8856f044f8d9305cd8f6551dd3f
work_keys_str_mv	AT ceskovae noveltreatmentoptionsindepressionandpsychosis AT silhanp noveltreatmentoptionsindepressionandpsychosis
_version_	1718402575590490112

Novel treatment options in depression and psychosis

Ejemplares similares